Characteristics and one-year outcomes of patients with advanced atrioventricular block in Saudi Arabia

References

1. 1.↵
   1. Alhabeeb W,
   2. Elasfar A,
   3. AlBackr H,
   4. AlShaer F,
   5. Almasood A,
   6. Alfaleh H, et al.

   Clinical characteristics, management and outcomes of patients with chronic heart failure: results from the heart function assessment registry trial in Saudi Arabia (HEARTS-chronic). Int J Cardiol 2017; 235: 94-99.

   OpenUrl
2. 2.↵
   1. Alhabib KF,
   2. Kinsara AJ,
   3. Alghamdi S,
   4. Al-Murayeh M,
   5. Hussein GA,
   6. AlSaif S, et al.

   The first survey of the Saudi acute myocardial infarction registry program: main results and long-term outcomes (STARS-1 Program). PLoS One 2019; 14: e0216551.

   OpenUrl
3. 3.↵
   1. Zubaid M,
   2. Rashed WA,
   3. Alsheikh-Ali AA,
   4. Almahmeed W,
   5. Shehab A,
   6. Sulaiman K, et al.

   Gulf survey of atrial fibrillation events (Gulf SAFE): design and baseline characteristics of patients with atrial fibrillation in the Arab Middle East. Circ Cardiovasc Qual Outcomes 2011; 4: 477-482.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Birnie DH,
   2. Sauer WH,
   3. Bogun F,
   4. Cooper JM,
   5. Culver DA,
   6. Duvernoy CS, et al.

   HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014; 11: 1305-1323.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Blomström-Lundqvist C,
   2. Traykov V,
   3. Erba PA,
   4. Burri H,
   5. Nielsen JC,
   6. Bongiorni MG, et al.

   European Heart Rhythm Association (EHRA) international consensus document on how to prevent, diagnose, and treat cardiac implantable electronic device infections-endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), International Society for Cardiovascular Infectious Diseases (ISCVID), and the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2020; 41: 2012-2032.

   OpenUrlPubMed
6. 6.↵
   1. Nery PB,
   2. Beanlands RS,
   3. Nair GM,
   4. Green M,
   5. Yang J,
   6. McArdle BA, et al.

   Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults. J Cardiovasc Electrophysiol 2014; 25: 875-881.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. Haxha S,
   2. Halili A,
   3. Malmborg M,
   4. Pedersen-Bjergaard U,
   5. Philbert BT,
   6. Lindhardt TB, et al.

   Type 2 diabetes mellitus and higher rate of complete atrioventricular block: a Danish Nationwide Registry. Eur Heart J 2023; 44: 752-761.

   OpenUrl
8. 8.↵
   1. Matsubara T,
   2. Sumiyoshi M,
   3. Kimura A,
   4. Minami-Takano A,
   5. Maruyama K,
   6. Kimura Y, et al.

   Trend in age at the initial pacemaker implantation in patients with Bradyarrhythmia - a 50-year analysis (1970-2019) in Japan. Circ J 2022; 86: 1292-1297.

   OpenUrl
9. 9.↵
   1. Mkoko P,
   2. Rajoo ST,
   3. Chin A

   . Causes of heart block in young and middle-aged South Africans. Curr Probl Cardiol 2023; 48: 101247.

   OpenUrl
10. 10.↵
    Statista. [Updated 2024; 2024 Feb 16]. Available from: https://www.statista.com/
11. 11.↵
    1. AlHabib KF,
    2. Elasfar AA,
    3. AlBackr H,
    4. AlFaleh H,
    5. Hersi A,
    6. AlShaer F, et al.

    Design and preliminary results of the heart function assessment registry trial in Saudi Arabia (HEARTS) in patients with acute and chronic heart failure. Eur J Heart Fail 2011; 13: 1178-1184.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Shan R,
    2. Ning Y,
    3. Ma Y,
    4. Liu S,
    5. Wu J,
    6. Fan X, et al.

    Prevalence and risk factors of atrioventricular block among 15 million Chinese health examination participants in 2018: a nation-wide cross-sectional study. BMC Cardiovasc Disord 2021; 21: 289.

    OpenUrl
13. 13.↵
    1. Nery PB,
    2. Beanlands RS,
    3. Nair GM,
    4. Green M,
    5. Yang J,
    6. McArdle BA, et al.

    Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults. J Cardiovasc Electrophysiol 2014; 25: 875-881.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Kandolin R,
    2. Lehtonen J,
    3. Kupari M

    . Cardiac sarcoidosis and giant cell myocarditis as causes of atrioventricular block in young and middle-aged adults. Circ Arrhythm Electrophysiol 2011; 4: 303-309.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Hena KM

    . Sarcoidosis epidemiology: race matters. Front Immunol 2020; 11: 537382.

    OpenUrlPubMed